稠环杂环化合物、或其药学上可接受的盐在制备治疗脑卒中药物中的应用
By inhibiting the TRPM2 channel with fused-ring heterocyclic compounds, the problem of the ineffectiveness of existing stroke treatment drugs was solved, and neuroprotective effects of reducing the area of cerebral infarction and enhancing autophagy function were achieved.
CN115073448BActive Publication Date: 2026-07-17HANGZHOU SHENGNUO HONGJIAN BIOTECHNOLOGY CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HANGZHOU SHENGNUO HONGJIAN BIOTECHNOLOGY CO LTD
- Filing Date
- 2021-03-11
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing stroke treatments lack effectiveness, failing to significantly reduce morbidity, mortality, and disability rates, and have no significant effect on ischemic stroke.
Method used
By using fused-ring heterocyclic compounds or their pharmaceutically acceptable salts, neuroprotection can be achieved by inhibiting TRPM2 channels, reducing the area of cerebral infarction, and enhancing autophagy during ischemia-reperfusion.
Benefits of technology
Fused-ring heterocyclic compounds significantly reduce the area of cerebral infarction, enhance autophagy, inhibit the accumulation of zinc ions in neurons, promote the repair of brain injury, and provide effective neuroprotection.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN115073448B_ABST
Abstract
本申请公开了一种稠环杂环化合物，或其药学上可接受的盐在制备治疗脑卒中药物中的应用。本申请中，稠环杂环化合物、或其药学上可接受的盐、立体异构体、溶剂化合物或前药，稠环杂环化合物具有通式(I)所示结构，具有显著减少脑梗死面积，增强缺血复灌过程中的自噬功能的作用从而实现脑保护，本发明为稠环杂环化合物开辟了新的应用领域，尤其是在制备治疗脑卒中药物应用方面。
Need to check novelty before this filing date? Find Prior Art